
Antibody	Company	Catalogue	Dilution	Application
name	Company	number	rate	
CD86	Santa cruz	10(17	1:100	Immunohistochemistry
	Biotechnology	sc-19617		
CD163	Santa cruz	a a a a a a a a a a a a a a a a a a a	1:100	Immunohistochemistry
	Biotechnology	sc-20066		
RAGE	Santa cruz Biotechnology	sc-365154 -	1:100	Immunohistochemistry
			ELISA	
			AGEs	Abcam
ELISA				
HMGB1	Abcam	ab 18256	1:1000	ELICA
				ELISA
S100β	Abcam	ab 52642	1:500	
				ELISA
β-actin		4967S	1:1000	
	Cell signaling			Immunoblotting
				Ũ

Table S1. List of antibodies for Immunoassay

Gene	Primer			
CD86	Forward	5'-AGCAACTAATGCTGAAAGCACA-3'		
	Reverse	5'-CTCAGACCTGCCAAAGTTCTCT-3'		
CD80	Forward	5'-AGCAACTAATGCTGAAAGCACA-3'		
	Reverse	5'-CTCAGACCTGCCAAAGTTCTCT-3'		
CD163	Forward	5'- AGTGCCTCCCAAAAATGACTT -3'		
	Reverse	5'- GACCAATAGAATGGCTCCACA-3'		
CD206	Forward	5'-AGCAACTAATGCTGAAAGCACA-3'		
	Reverse	5'-CTCAGACCTGCCAAAGTTCTCT-3'		
TNF-α	Forward	5'-TTCTGTCTACTGAACTTCGGGGTGATCGGTCC-3'		
	Reverse	5'-GTATGAGATAGCAAATCGGCTGACGGTGTGGG-3'		
IL-1β	Forward	5'-CCTTTTCGTGAATGAGCAGAC -3'		
	Reverse	5'-AGAATGTGCCATGGTTTCTTG-3'		
β-actin	Forward	5'-ACAAAGCTGTTCAGTGTCTCCA-3'		
	Reverse	5'-CTCCGTTTCCAGAATACACACA-3'		


Table S2. List of primer for quantitative polymerase chain reaction

Figure S1. Inhibiting effects of PPB on the expression of RAGE in visceral fat




Fluorescence intensity of RAGE in visceral fat. Significance represented as **, *p* <0.01 versus Control; ##, *p* <0.01 versus DIO/Saline. DIO, diet-induced obesity; PPB, pyrogallol-phloroglucinol-6,6-bieckol; RAGE, receptor for advanced glycation end-products.

Figure S2. Regulating effects of PPB on M1 and M2 type macrophage differentiation in visceral fat



(A) Immunohistochemical images (CD86) and (B) quantified intensity graph are measured in visceral fat. (C) Immunohistochemical images (CD163) and (D) quantified intensity graph are measured in visceral fat. Scale bar = 200 μ m; x400 magnification. The significance represented as **, *p* <0.01 versus Control; #, *p* <0.05 and ##, *p* <0.01 versus DIO/Saline. DAB, 3, 3-diaminobenzidine; DIO, diet-induced obesity; PPB, pyrogallol-phloroglucinol-6,6-bieckol

Figure S3. Visceral fat protein purification for control, DIO/Saline and PPB



(A) Coomassie blue staining and (B) immunoblotting for β -actin were used for visceral fat protein purification. DIO, diet-induced obesity; PPB, pyrogallol-phloroglucinol-6,6-bieckol